Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

Afternoon session key learning objectives:

1:30 pm - Monday 12th October 2026

Gaining an understanding of the biological aspects of ADCs
Selecting the most appropriate ADC target
Choosing an optimum antibody format
Analyzing the choices and trade-offs in utilizing the chemistry ADC toolbox
Assessing key factors in the evaluation of efficacy information from in vivo preclinical models